Why the study?
To better understand the molecular basis for PAR4-dependent signaling, a GPCR that represents an important target in the development of anti-platelet therapeutics.
This basic science study explores the molecular basis of PAR4 activation and biased signaling using a peptide library, which may inform the development of novel anti-platelet therapeutics.
PAR4 activation mechanisms mapped in vitro; leaves open whether biased signaling can improve antiplatelet safety.
Proteinase-activated receptor (PAR)-4 is a member of the proteolytically-activated PAR family of G-protein-coupled receptors (GPCR) that represents an important target in the development of anti-platelet therapeutics. PARs are activated by proteolytic cleavage of their receptor N terminus by enzymes such as thrombin, trypsin, and cathepsin-G. This reveals the receptor-activating motif, termed the tethered ligand that binds intramolecularly to the receptor and triggers signaling. However, PARs are also activated by exogenous application of synthetic peptides derived from the tethered-ligand sequence. To better understand the molecular basis for PAR4-dependent signaling, we examined PAR4-signaling responses to a peptide library derived from the canonical PAR4-agonist peptide, AYPGKF-NH 2 , and we monitored activation of the G q/11 -coupled calcium-signaling pathway, -arrestin recruitment, and mitogen-activated protein kinase (MAPK) pathway activation.
No takes yet. Share an insight, caveat, or question.
Thibeault et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: